

PRODUCT INFORMATION




Tetrabenazine-d₆

Item No. 26811

CAS Registry No.: 1392826-25-3
Formal Name: *rel*-1,3R,4,6,7,11bR-hexahydro-9,10-di(methoxy-d₃)-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one

Synonym: TBZ-d₆
MF: C₁₉H₂₁D₆NO₃
FW: 323.5
Chemical Purity: ≥98% (Tetrabenazine)

Deuterium Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tetrabenazine-d₆ is intended for use as an internal standard for the quantification of tetrabenazine (Item No. 20380) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Tetrabenazine-d₆ is supplied as a crystalline solid. A stock solution may be made by dissolving the tetrabenazine-d₆ in the solvent of choice. Tetrabenazine-d₆ is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of tetrabenazine-d₆ in these solvents is approximately 10, 25, and 30 mg/ml, respectively.

Description

Tetrabenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2) that is selective over VMAT1 (K_is = 97 and >20,000 nM, respectively, in a serotonin uptake assay).¹ It dose-dependently reduces levels of the monoamines norepinephrine (Item No. 16673), dopamine (Item No. 21992), and serotonin (5-HT; Item No. 14332) in rat brain and has been used to induce depressive-like behavior in animal models.^{2,3} Tetrabenazine (5 mg/kg) improves performance in balance beam and rotarod tests and prevents decreases in the number of striatal medium spiny neurons (MSNs) in a YAC128 transgenic mouse model of Huntington's disease.⁴ Formulations containing tetrabenazine have been used in the treatment of chorea associated with Huntington's disease.

References

1. Erickson, J.D., Schäfer, M.K.H., Bonner, T.I., *et al.* *Proc. Natl. Acad. Sci. U.S.A.* **93**(10), 5166-5171 (1996).
2. Pettibone, D.J., Totaro, J.A., and Pflueger, A.B. *Eur. J. Pharmacol.* **102**(3-4), 425-430 (1984).
3. Preskorn, S.H., Kent, T.A., Glotzbach, R.K., *et al.* *Psychopharmacology (Berl)*. **84**(2), 196-199 (1984).
4. Wang, H., Chen, X., Li, Y., *et al.* *Mol. Neurodegener.* **5**:18 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM